Protons 101: A Summary of the More Business Slanted Posts and one on ChatGPT just cause :)
A brief summary linking to past articles for those new to the site
www.protons101.com
Home to the musings of a radiation oncologist - with a slant on protons and dose and optimizing cancer outcomes.
Last week the proton / money / death star post garnered more attention and many new subscribers. First, thank you for the support! Many articles here are quite medically related, but it seems about 20% or so have taken on a business / financial perspective.
Today is a summary link to those more business slanted articles here on the site with a brief description of it’s link to the business side of medicine, we’ll call it the Protons 101: Business Collection:
PROTONS 101: Business Collection
A look at the cost structure of these facilities. I think any physician considering leadership, setting pay structures for their staff or considering capital equipment might gain something.
A look that gives perspective on the scale of our field to the broader pharmaceutical industry asking how we can better compete.
Less business than the above, but if you’ve never sat on a board, I think it provides insight. Radiation Oncology revenues, across the board, are stable to declining and that has real impact on capital decisions that you should be aware of.
A look at market forces: SBRT, hypofractionation, and a move to radiation avoidance trials. A proposal / concept of a way to perhaps look at addressing issues as one suggestion to help address what appears to be an imbalance in our market.
This one focuses on MRI Linac trials. To me, the ethical issues related to proton therapy are not just with protons, but more accurately related to capital costs and technology. This is a discussion along those lines beginning to ask how we will deal with studies that demonstrate some equipment is stronger than others.
And finally, ChatGPT. I mean, really, can you write something in 2023 and not have an AI example.
Thanks again for support! This weekend, the plan is to continue our look at the high risk prostate cancer and then to look at randomized proton studies out of Europe and then have a bit of discussion on radiation history and why this data is critical to the proton therapy industry.
Have a great week and keep pushing for better!